



23 January 2026

Novartis Pharma AG
Basel, Switzerland
CH-4056

Reference: EudraCT 2021-006950-30 Novartis Protocol ID CLOU064I12201.

A one month, investigator and participant blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy

Trial 2021-006950-30 was cancelled in the EU/EEA with no patient enrollment and as such, no results will be reported.